School of Pharmacy Celebrates the Class of 2016 at Convocation
May 20, 2016
More than 200 PharmD and graduate students receive degrees and embark on the next phase of their lives.
May 20, 2016
More than 200 PharmD and graduate students receive degrees and embark on the next phase of their lives.
May 16, 2016
Fellowships will provide students with the hands-on experience and leadership skills needed to pursue careers in clinical drug development.
April 22, 2016
Research Day offers an opportunity for students and trainees to showcase their current research and network with potential collaborators.
March 24, 2016
FDA praises the Center’s efforts to bring academic, government, and industry stakeholders together for collaborative project with wide-reaching implications.
February 23, 2016
More than 100 faculty, staff, students, alumni, and guests gather in Pharmacy Hall to kick-off the School’s anniversary with a grand birthday celebration.
February 19, 2016
Fourth annual M-CERSI “America’s Got Regulatory Science Talent” competition awards third-year student pharmacists first prize for novel solution to improve FDA’s post-marketing surveillance program.
December 8, 2015
First-of-its-kind event brings alumni from the PhD in Pharmaceutical Sciences (PSC) program together to reconnect with the School and discuss career experiences with current graduate students.
December 7, 2015
New grants and contracts from a multitude of non-profit and government organizations, as well as the private sector, help the School of Pharmacy achieve the highest funding increase among all professional and graduate schools at the University of Maryland, Baltimore.
October 29, 2015
Leading health solutions company will support genotyping services for students in the School’s advanced pharmacogenomics course.
August 28, 2015
More than 500 researchers from academia, government, and industry gather to gain perspective on biomarker development and the application of biomarkers in preclinical and clinical research.
August 14, 2015
Collaborative study helps validate effectiveness of FDA’s bioequivalence standard, showing no significant differences between major brand name and generic medication used to treat patients with epilepsy.
August 6, 2015
Testimony examined the impact of FDA-supported research in generic drugs and advocated for continued funding through renewal of the Generic Drug User Fee Amendments of 2012 (GDUFA).